Scientists deliberately infect volunteers with whooping cough to speed up vaccine research
NCT ID NCT06827470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a safe, controlled human infection model for whooping cough. Healthy adults aged 18-50 will receive a nasal dose of the bacteria to cause a mild infection. Researchers will monitor symptoms and test nasal samples to find the best dose that infects most people safely. This model will help test future vaccines and treatments more efficiently.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS (WHOOPING COUGH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Canadian Center for Vaccinology
RECRUITINGHalifax, Nova Scotia, B3K 6R8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine trial aims to shield teens and adults from whooping cough
- Thousands monitored: is the whooping cough vaccine safe in real life?
- Whooping cough vaccine safety under the microscope in thailand
- Massive U.S. study to see if whooping cough vaccine is safe for pregnant women and babies
- New whooping cough vaccine shows promise for toddlers
- Whooping cough vaccine safety checked in 2,700 thai moms and babies